Ventricular Assist Device Market is Predicted to Grow at a CAGR of 10.1% Over the Forecast Period; New Product Launches and Expansion of Production Capacity Boost Market Development

The ventricular assist device market size was valued at USD 1.49 billion in 2025. The market is projected to grow from USD 1.64 billion in 2026 to USD 3.54 billion by 2034, exhibiting a CAGR of 10.1% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, “Ventricular Assist Device Market Size, Share & Industry Analysis, By Product (Left Ventricular Assist Device, Right Ventricular Assist Device, and Bi-Ventricular Assist Device), By Type of Flow (Pulsatile Flow and Continuous Flow), By Application (Bridge to Transplant (BTT), Bridge to Candidacy (BTC), Destination Therapy (DT), and Bridge to Recovery (BTR)), By End-user (Hospitals & ASCs and Specialty Clinics & Others), and Regional Forecast, 2026-2034”.

Ventricular assist devices offer mechanical circulatory aid for heart failure patients with severe symptoms. They pump blood from the heart chamber to the whole body mechanically. The growing occurrence of heart failure conditions is driving the market expansion. For instance, the Journal of Cardiac Failure, in 2023, stated that around 6.7 million Americans aged 20 and above are suffering from heart failure. Additionally, this number is likely to reach 8.5 million by 2030. Market players including Abbott, Berlin Heart, and ABIOMED are increasing their focus on research and development to introduce efficient devices in the marketplace.

Partnership Between Supira, Hillcrest and Oklahoma Heart Institute Boosts Market Development

In August 2026, Supira partnered with Hillcrest and Oklahoma Heart Institute. This partnership aims to bring the SUPPORT II pivotal trial of its investigational pVAD system to Tulsa, Oklahoma.

Growing Prevalence of Heart Failure Cases Propels Market Development

Increasing occurrence of heart failure conditions globally is boosting the ventricular assist device market growth. It is one of the major leading causes of death worldwide, impacting more than 1 to 2% of the population across Western countries. The American Heart Association also reported that around 6.7 million adults were living with heart failure in 2025, whereas the number is expected to exceed 8 million by 2030. Mechanical circulatory support devices are preferred to assist cardiac circulation when medications are not effective, and heart transplantation is not feasible. This is used to either completely or partially replace the function of a failing heart. Mechanical support systems consist of ventricular assist devices, extracorporeal membrane oxygenator (ECMO) pumps, intra-aortic balloon pumps (IABP), and total artificial heart (TAH).

However, the high cost associated with these devices restricts the ventricular assist device market growth.

Key Players’ Focus on Innovation and Boosting Sales to Sustain their Market Position

Key players across the globe are capturing a significant share of the market due to their strong sales and brand reputation. Additionally, these firms are focusing on strategic initiatives to expand their product offerings. Several companies have their product in the research and development stage, and the launch of these products is predicted to capture significant market share in the future.

Notable Industry Development

• August 2026: Berlin Heart received U.S. FDA approval for an alteration to the EXCOR Pediatric VAD blood pumps. This has allowed the use of polyurethane to seal the de-airing port plug.

List of Key Companies Profiled in the Report

• Berlin Heart (Germany)
• ABIOMED (U.S.)
• Abbott (U.S.)
• magAssist Co., Ltd. (China)
• NIPRO (Japan)
• PulseCath (Netherlands)
• Suzhou Tongxin Medical Technology Co., Ltd. (China)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/ventricular-assist-device-market-106377

Further Report Findings

• North America held the largest ventricular assist device market share, due to the increasing prevalence of cardiovascular diseases and heart transplantation rates across the region.
• Europe’s market growth is attributed to growing investment in the development of ventricular assist devices and the presence of major key players in the region.
• Market expansion in Asia Pacific is due to advancements in medical facilities and favourable legal government policies.
• In terms of end user, the hospitals & ASCs segment led due to growing hospital stays of patients who are undergoing heart surgeries, including device placement or implant procedures.

Table of Segmentation